Gemcitabine

Generic Name
Gemcitabine
Brand Names
Gemzar
Drug Type
Small Molecule
Chemical Formula
C9H11F2N3O4
CAS Number
95058-81-4
Unique Ingredient Identifier
B76N6SBZ8R
Background

Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...

Indication

Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.

In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...

Associated Conditions
Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

A Phase III Trial For Patients With Metastatic Breast Cancer

First Posted Date
2005-09-19
Last Posted Date
2009-12-24
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
475
Registration Number
NCT00191152
Locations
🇲🇽

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Michoacan, Mexico

🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Taipei, Taiwan

🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Tao-Yuan, Taiwan

and more 1 locations

A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer

First Posted Date
2005-09-19
Last Posted Date
2009-11-20
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
150
Registration Number
NCT00191451
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States

Combination Chemotherapy for Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: Gemcitabine
Drug: cisplatin
First Posted Date
2005-09-19
Last Posted Date
2009-11-11
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
70
Registration Number
NCT00191815
Locations
🇷🇺

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9AM to 5PM Eastern time (UTC/ GMT - 5hours, EST), or speak with your personal physician, Moscow, Russian Federation

Instillation of Gemcitabine in Patients With Superficial Bladder Cancer

Phase 3
Terminated
Conditions
Bladder Neoplasms
Interventions
Drug: Gemcitabine
Drug: Placebo
First Posted Date
2005-09-19
Last Posted Date
2009-10-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
355
Registration Number
NCT00191477
Locations
🇩🇪

For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559,1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physici, Reinfeld, Germany

Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes

Phase 2
Completed
Conditions
Metastatic Breast Cancer
First Posted Date
2005-09-19
Last Posted Date
2007-11-20
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
100
Registration Number
NCT00192101
Locations
🇸🇦

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Jeddah, Saudi Arabia

A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer

Phase 3
Completed
Conditions
Non-Small Cell Lung Cancer
First Posted Date
2005-09-19
Last Posted Date
2007-11-14
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
242
Registration Number
NCT00190710
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of Non Small Cell Lung Cancer

Phase 2
Completed
Conditions
Carcinoma, Non-Small-Cell-Lung Cancer
First Posted Date
2005-09-19
Last Posted Date
2007-11-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
52
Registration Number
NCT00191763
Locations
🇹🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Istanbul, Turkey

2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

First Posted Date
2005-09-19
Last Posted Date
2007-11-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
40
Registration Number
NCT00191971
Locations
🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tokyo, Japan

Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer

Phase 2
Completed
Conditions
Pancreatic Neoplasms
First Posted Date
2005-09-19
Last Posted Date
2007-10-19
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
45
Registration Number
NCT00191568
Locations
🇫🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) MON-FRI 9 AM - 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Pierre Benite, France

A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease

First Posted Date
2005-09-19
Last Posted Date
2007-09-12
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
66
Registration Number
NCT00191373
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CT-LILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ogden, Utah, United States

🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morgantown, West Virginia, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy